Biogen Inc. buy Royal Bank of Canada
Start price
19.09.24
/
50%
€180.40
Target price
19.09.25
€262.25
Performance (%)
-32.93%
End price
20.09.25
€121.00
Summary
This prediction ended on 20.09.25 with a price of €121.00. The BUY prediction by Royal_Bank_of_Canada for Biogen Inc. performed very badly with a performance of -32.93%. Royal_Bank_of_Canada has a follow-up prediction for Biogen Inc. where he still thinks Biogen Inc. is a Buy. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biogen Inc. | 7.077% | 7.077% | 18.809% |
| iShares Core DAX® | 0.754% | -1.027% | 14.485% |
| iShares Nasdaq 100 | -2.859% | -4.266% | 2.185% |
| iShares Nikkei 225® | 4.946% | 5.736% | 25.355% |
| iShares S&P 500 | -1.254% | -2.357% | 1.146% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $292.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
In the thread Trading Biogen Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten

